Investor Centre
Investor Centre
The International Finance Facility for Immunisation (IFFIm) exists to rapidly accelerate the availability and predictability of funds for immunisation
Vaccine Bonds: financing immunisation and saving lives
Vaccines are one of the most successful and cost-effective health investments in the world, with wider benefits that accrue across a lifetime. A 2020 analysis by the Decade of Vaccine Economics (DoVE) Project found that each US$ 1 of investment in immunisation will give a return of US$ 21 dollars, rising to US$ 54 when broader societal benefits are included. By comparison, publicly traded American companies in the S&P 500 have returned an average of US$ 2.16 for every US$ 1 invested after ten years.
Moreover, investments in vaccination programmes will likely result in US$ 0.8 trillion in returns over the next ten years. This net benefit is about 20 times larger than the costs forecasted for vaccination programmes over the next ten years, from 2021-30.
Impact investors can support Gavi’s life-saving immunisation programmes through purchasing IFFIm Vaccine Bonds. IFFIm issues these “pure play” bonds in the capital markets, converting long-term pledges from donor governments into immediate cash resources for Gavi.
The Wall Street Journal calls IFFIm “one of the most successful bond-efforts to-date” and IFFIm has won numerous awards and recognitions for its leadership in innovative finance. Fitch Ratings, Moody's Investor Service and Standard & Poor's have rated IFFIm as AA-/Aa1/AA. IFFIm consistently earns an A/A+ rating from the U.K.’s Foreign, Commonwealth and Development Office (FCDO).
Investor Presentation
Learn more by downloading the Vaccine Bond investor presentation.
Previous issuances
IFFIm Vaccine Bonds have been issued in Japan, the UK, Australia and in the Eurobond market. IFFIm also has issued sukuks in the Islamic finance market. Use our timeline to chart all issuances in capital markets around the world since the inaugural benchmark launch in London in 2006.
Learn moreRating reports
Fitch Ratings, Moody's Investor Service and Standard & Poor's have rated IFFIm as AA-/Aa1/AA.
View allSocial Bond Principles
IFFIm’s pioneering Vaccine Bonds have been instrumental in influencing the financial markets to develop a set of common Social Bond Principles to underpin this market.
Learn moreBond documentation
Download documents on Global Debt Issuance Programme, Pricing Supplements and Australian and New Zealand Medium-Term Note Programme.
View all
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.